Delving into the Latest Updates on Etripamil with Synapse

This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-up and Post-treatment Follow-up Visits), a Final Study Visit, and an End of Study Telephone Follow up Visit.
Each patient will be randomized 1:1 to receive placebo or 70 mg Etripamil NS regimens. Patients will self-administer study drug for a perceived episode of AF with RVR with an initial dose of placebo or 70 mg etripamil NS, followed by an optional second dose of the same study drug 10 minutes after the first dose if the patient continues to experience symptoms. Patients may treat up to a maximum of 4 episodes in the study.
Informed consent will be obtained prior to any study procedures.

Start Date01 Jan 2027

Sponsor / Collaborator

Milestone Pharmaceuticals, Inc.

NCT05763953

/ RecruitingPhase 2

The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia

NODE-202 is a Phase 2, multicenter, multinational, single dose, open-label, 2-part, sequential design study in pediatric patients with an established diagnosis of paroxysmal supraventricular tachycardia (PSVT) presenting with a symptomatic episode of PSVT.
In Part 1, at least 30 patients aged 12 to <18 years will be enrolled and treated with etripamil nasal spray (NS). Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of 70 mg etripamil NS (Part 1A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the Pharmacokinetic (PK) analysis and will undergo efficacy and safety/tolerability assessments (Part 1B).
In Part 2, at least 30 patients aged 6 to <12 years will be enrolled and treated with etripamil NS at a dose selected based on appropriate body size-based modeling, as well as efficacy, safety/tolerability, and PK data collected in Part 1. Efficacy, safety, tolerability and PK (for at least 12 patients) will be assessed after administration of etripamil NS (Part 2A). At least 18 subsequent patients will be enrolled and treated with the etripamil NS with the dose determined by the PK analysis and will undergo efficacy and safety/tolerability assessments (Part 2B).
The study will include the following visits: A Screening Visit, A Treatment Visit, , and A Follow-Up/End of Study Visit.

Start Date11 Dec 2023

Sponsor / Collaborator

Milestone Pharmaceuticals, Inc.

NCT05511870

/ CompletedPhase 1

A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Etripamil in Healthy Chinese Subjects

The objectives of the study are as below:
Primary:
·To evaluate the pharmacokinetics (PK) of Etripamil in healthy adult Chinese subjects
Secondary:
* To evaluate the pharmacodynamics (PD) of Etripamil in healthy adult Chinese subjects
* To evaluate the safety and tolerability of Etripamil in healthy adult Chinese subjects
Exploratory:
·To evaluate the PK exposure-PD response relationship of etripamil in healthy adult Chinese subjects

Start Date07 Mar 2023

Sponsor / Collaborator

Milestone Pharmaceuticals, Inc.

100 Clinical Results associated with Etripamil

Login to view more data

100 Translational Medicine associated with Etripamil

Login to view more data

100 Patents (Medical) associated with Etripamil

Login to view more data

40

Literatures (Medical) associated with Etripamil

19 May 2026·European Heart Journal-Cardiovascular Pharmacotherapy

Cardiovascular pharmacotherapy in 2025

Review

Author: Tamargo, Juan ; Ferdinandy, Péter ; Drexel, Heinz ; Rocca, Bianca ; Semb, Anne Grete ; Kaski, Juan Carlos ; Borghi, Claudio ; Ambrosio, Giuseppe ; Dan, Gheorghe A ; Parker, William ; Sossalla, Samuel ; Dobrev, Dobromir ; Morais, Joao ; Cerbai, Elisabetta ; Grove, Erik Lerkevang ; Agewall, Stefan ; Sulzgruber, Patrick ; Klingenberg, Roland

Abstract:

Despite recent advances in cardiovascular pharmacotherapy, prevention and treatment of many cardiovascular diseases remain limited with a clear need for more effective and safer pharmacological strategies. Here, we summarize the most relevant advances in cardiovascular pharmacotherapy in 2025, including the approval of four new drugs (aficamten, etripamil, lerodalcibep, and plozasiran), the label expansions for five already approved drugs, and the results of major randomized clinical trials with already approved drugs, including those that met the prespecified primary endpoints (positive trials) representing new pharmacological options for cardiovascular diseases, those with neutral or negative results, which did not confirm the primary endpoints and the withdrawal from the US market of Andexanet-alfa for safety concerns. Finally, we present the most promising experimental cardiovascular drugs currently being investigated in ongoing Phase 2 and 3 clinical trials.

02 May 2026·DRUGS

Etripamil: First Approval.

Article

Author: Brown, Michael B

Etripamil (CARDAMYST^TM) is an intranasal L-type calcium channel blocker (CCB) developed by Milestone Pharmaceuticals for the treatment of symptomatic paroxysmal supraventricular tachycardia (PSVT) and is under investigation for atrial fibrillation with rapid ventricular rate (AF-RVR). It received its first approval on the 12 December 2025 in the USA for the conversion of acute symptomatic PSVT episodes to sinus rhythm in adults. Additional global regulatory filings of etripamil for PSVT in adults, a phase II trial of etripamil in pediatrics, and a phase III trial for AF-RVR are in progress. This article summarizes the milestones in the development of etripamil leading to this first approval for PSVT.

01 May 2026·HEART RHYTHM

A review of etripamil: A new paradigm for treating paroxysmal supraventricular tachycardia for an informed, shared decision

Review

Author: Ip, James E

Paroxysmal supraventricular tachycardia (PSVT) is associated with significant morbidity and affects 1 in 300 people. This article reviews the contemporary management of PSVT and the potential role of intranasal etripamil, a recently Food and Drug Administration-approved intranasal calcium channel blocker that can be used to safely and effectively terminate PSVT in an outpatient setting and avoid urgent medical attention. When combined with the use of wearable devices, this paradigm shift of enabling patients to self-treat PSVT with an on-demand therapy provides another option to be considered in shared decision making for PSVT management.

119

News (Medical) associated with Etripamil

03 Jul 2026

·www.globenewswire.com

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder. The foregoing equity award was granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4). About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR. Contact:Kevin Gardner kgardner@lifesciadvisors.com

Drug Approval

03 Jul 2026

·www.biospace.com

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 2, 2026

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees. The Options have a grant date of July 1, 2026, and an exercise price of $1.32 per share, which is equal to the closing price of Milestone’s common shares on the grant date. The shares subject to the Options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder. The foregoing equity award was granted as an inducement material to the employees entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4). About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR. Contact: Kevin Gardner kgardner@lifesciadvisors.com

Drug Approval

14 May 2026

·www.biospace.com

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York. A live webcast of the fireside chat will be available to conference participants on May 19 th at 3:00pm ET. The webcast is available to watch both live and replay for approximately 90-days following the presentation on the News & Events section of Milestone's website . If you are interested in meeting with the Milestone team during the conference, please contact your H.C. Wainwright representative. About Milestone Pharmaceuticals Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the control of symptomatic episodic attacks associated with AFib-RVR. Contact: Investor Relations Kevin Gardner, kgardner@lifesciadvisors.com Media Relations Rebecca Novak, rnovak@milestonepharma.com

100 Deals associated with Etripamil

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10932	-	-	DB12605

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Paroxysmal supraventricular tachycardia	United States	Milestone Pharmaceuticals USA, Inc.	12 Dec 2025

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 3	-	Milestone Pharmaceuticals, Inc.	01 Jan 2027
Episodic Ataxia	Phase 3	China	Milestone Pharmaceuticals, Inc.	30 Jun 2022
Episodic Ataxia	Phase 3	China	Corxel Pharmaceuticals (Shanghai) Co., Ltd	30 Jun 2022
Tachycardia, Supraventricular	Phase 3	China	Milestone Pharmaceuticals, Inc.	30 Jun 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04072835 (NODE-303, Pubmed \| J Cardiovasc Electrophysiol)	Phase 3	Atrial Fibrillation	18	Etripamil Nasal Spray (Atrial Fibrillation)	ukyorenrfa(aculxjudhx) = louydcbgez ijebkhydld (lghbnhktuj ) View more	Positive	10 Feb 2026
NCT04072835 (NODE-303, Pubmed \| J Cardiovasc Electrophysiol)	Phase 3	Paroxysmal supraventricular tachycardia	1,116	Etripamil 70 mg	srwfnyuowt(ditwzakcwm) = imrtcgboha johzwlxusg (ryxzogtjqd )	Positive	01 Nov 2025
NCT04467905 (ReVeRA-201, CTgov)	Phase 2	Atrial Fibrillation	69	Placebo (Placebo)	vrwwwvaiaf(gddckwojqh) = sybvxjubmz lmhlyzppzq (dpczksphya, 13.9) View more	-	19 Sep 2024
				Etripamil (Etripamil)	vrwwwvaiaf(gddckwojqh) = clqxnwxron lmhlyzppzq (dpczksphya, 15.3) View more
NCT05410860 (JX02002, GlobeNewswire) Manual	Phase 3	Paroxysmal supraventricular tachycardia	500	etripamil	cpecoanmbv(cvwieosslz) = vanxgeygpn kmkqnudznb (wkigruyimg ) Met	Positive	06 Sep 2024
				Placebo	cpecoanmbv(cvwieosslz) = szenhzlnrd kmkqnudznb (wkigruyimg ) Met
NCT03464019 (NODE-301 \| RAPID, CTgov)	Phase 3	Paroxysmal supraventricular tachycardia	1,097	Placebo (Part 1 - Placebo Single Dose)	xezunkoanh = iqiclemnky uksqygoblg (dvzpehtiqy, qiifmdozjd - khwenyaxcy) View more	-	12 Jul 2024
				Etripamil (Part 1 - Etripamil 70 mg)	xezunkoanh = nmslmnjviy uksqygoblg (dvzpehtiqy, hjkoerelzr - dzwkkwbceb) View more
NCT04072835 (NODE-303, CTgov)	Phase 3	Paroxysmal supraventricular tachycardia	1,116	etripamil NS	malqmbooox(tfxpcgqrtw) = ucufddkogs huuzwrqeft (ypcfikbkdj, dexragwbif - pkuqillkrp) View more	-	23 May 2024
NCT04467905 (ReVeRA-201, Pubmed \| Circ Arrhythm Electrophysiol)	Phase 2	Atrial Fibrillation	-	Etripamil nasal spray 70 mg	jxnmjjnrui(etrlpqfgvg) = 1 patient in the etripamil arm experienced transient severe bradycardia and syncope, assessed as due to hypervagotonia xqjrdfzlrh (icgjqnsnps ) View more	Positive	01 Dec 2023
NCT03464019 (RAPID, Pubmed \| Lancet)	Phase 3	Paroxysmal supraventricular tachycardia \| Tachycardia, Atrioventricular Nodal Reentry	692	Etripamil 70 mg nasal spray	ihljpqvpcf(xldpjtenfo) = Adverse events occurring in at least 5% of patients treated with etripamil were nasal discomfort (23%), nasal congestion (13%), and rhinorrhea (9%) exdfciuirj (tqveyvyrup ) View more	Positive	01 Jul 2023
				Placebo
NCT03635996 (NODE-302, CTgov)	Phase 3	Paroxysmal supraventricular tachycardia	169	Aptar Pharma Nasal Spray Bidose System+Etripamil NS 70 mg	lmrnjlnhsy(hroswlznyw) = bqpzqfvfxx ttonwxwcjb (pteujhnwkg, rzozyzzbdc - fvpwxfbkur) View more	-	24 Apr 2023
NCT03464019 (NODE-301, Pubmed) Manual	Phase 3	Paroxysmal supraventricular tachycardia	156	Etripamil	uixduoootb(dmmwhnfawv): HR = 1.086 (95% CI, 0.726 - 1.623), P-Value = 0.12	Negative	28 Nov 2022
				Placebo